Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Traws Pharma (TRAW) Cash from Financing Activities (2016 - 2025)

Traws Pharma (TRAW) has disclosed Cash from Financing Activities for 12 consecutive years, with $158000.0 as the latest value for Q4 2025.

  • For Q4 2025, Cash from Financing Activities fell 99.21% year-over-year to $158000.0; the TTM value through Dec 2025 reached $3.2 million, down 91.97%, while the annual FY2025 figure was $3.2 million, 90.57% down from the prior year.
  • Cash from Financing Activities hit $158000.0 in Q4 2025 for Traws Pharma, up from -$62000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $35.6 million in Q1 2021 and bottomed at -$62000.0 in Q3 2025.
  • Average Cash from Financing Activities over 3 years is $8.7 million, with a median of $158000.0 recorded in 2025.
  • On a YoY basis, Cash from Financing Activities climbed as much as 633.77% in 2021 and fell as far as 112.54% in 2021.
  • Traws Pharma's Cash from Financing Activities stood at -$35000.0 in 2021, then skyrocketed by 57177.14% to $20.0 million in 2024, then tumbled by 99.21% to $158000.0 in 2025.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at $158000.0, -$62000.0, and $3.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.